Skip to content

RVMDW

Revolution Medicines, Inc.

NASDAQ · Healthcare · Biotechnology · US

$8.69
+3.45%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
-81.3%
EPS
-96.5%
Free cash flow
-75.9%
Operating cash flow
-78.6%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+15.5%
EPS
+20.5%

Three-year CAGR

Revenue
—
EBITDA
-85.1%
EBIT
-71.5%
Net income
-88.5%
EPS
-66.2%
Free cash flow
-60.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026